Methodist Healthcare Adopts IR-MED’s PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
10 sept. 2024 09h15 HE
|
IR-Med, Inc.
Patient enrollment and monitoring with PressureSafe™ has commencedIn a similar study conducted at the world’s 2nd largest HMO, PressureSafe™ had efficacy of 92% in detection and the incidence of...
IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company
21 août 2024 09h10 HE
|
IR-Med, Inc.
Rosh Pina, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis...
IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers
15 juil. 2024 09h15 HE
|
IR-Med, Inc.
DiaSafe™, IR-MED’s second product, is being developed to provide safe, real-time optical readings of biomarkers to detect the early presence of diabetic foot ulcers with high accuracyThe most common...
IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO
22 mai 2024 09h15 HE
|
IR-Med, Inc.
Poster presentation available here: LINK Rosh Pina, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial...
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
20 févr. 2024 09h15 HE
|
IR-Med, Inc.
Incidence of pressure injuries reduced by 50% during the study periodAs a decision support device, PressureSafe, can support early detection of pressure injuries, potentially setting a new standard of...
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
13 févr. 2024 09h15 HE
|
IR-Med, Inc.
Final results to be reported from a study conducted at two medical centers owned by Clalit, the world’s second largest health maintenance organization (HMO) and the largest in Israel PressureSafe, for...
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
07 déc. 2023 09h15 HE
|
IR-Med, Inc.
The Granted patent covers IR-MED’s PressureSafe™ decision support device for the early detection of pressure injuries addressing a healthcare burden that amounts to $26.8 billion in the U.S. annually...
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
04 oct. 2023 16h05 HE
|
IR-Med, Inc.
Mr. Di-Cori’s vast healthcare experience includes President of LifeWatch Technologies, a developer of technologies that help physicians detect symptoms before they become major health problems Rosh...
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024
26 sept. 2023 09h00 HE
|
IR-Med, Inc.
Study to address the substantial challenge of healthcare inequality in the early detection of pressure injuries in people of dark skin tonesPressureSafe, a skin-color agnostic decision support device,...
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board
13 sept. 2023 09h15 HE
|
IR-Med, Inc.
Served as Chief FDA Counsel for Revlon and Johnson & Johnson, as a Board Member at Johnson & Johnson Development Corporation, that company’s strategic venture capital division, and as patent...